SAN ANTONIO, TX
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Gencure, founded in 2013, is a community nonprofit in the Health Care sector that reported $5.4M in total revenue in fiscal year 2024. Expenses of $16.0M exceeded revenue, resulting in a 196% operating deficit.
GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical (CONTINUED ON SCHEDULE O)
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $5,427,037 | $5,040,198 | +0.1% |
| Expenses | $16,040,341 | $15,033,401 | +0.1% |
| Net Income | $-10,613,304 | $-9,993,203 | +0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| BIOBRIDGE GLOBAL | SOLE MEMBER | 1.0 |
|
$0 | $0 | $0 |
| GEOFFREY KINDT | General Manager, Biomanufacturing (thru 11/02/2024) | 50.0 |
Key Emp
|
$260,606 | $84,913 | $374,356 |
| AMANDA WHITELONIS | Principal Global Market Development (effective 11/03/2024) | 50.0 |
Highest
|
$20,119 | $27,276 | $219,270 |
| MARI LANE SALMI | SR. DIRECTOR, PROCESS DEV & CELL THERAPIES | 50.0 |
Highest
|
$203,361 | $40,993 | $244,354 |
| Miguel Garza | Director, Operations Biomanufacturing | 50.0 |
Highest
|
$156,301 | $19,855 | $176,156 |
| MILTON MASAYUKI POLLARD | VP, GENCURE OPERATIONS (thru 07/09/2024) | 50.0 |
Highest
|
$196,274 | $23,473 | $219,747 |
| ROGELIO ZAMILPA | Executive Director, Biomanufacturing & Collab | 50.0 |
Highest
|
$215,099 | $27,522 | $242,621 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $5,427,037 | $16,040,341 | $23,694,605 | $-10,613,304 |
| 2023 | $5,040,198 | $15,033,401 | $18,815,048 | $-9,993,203 |
| 2022 | $5,012,409 | $13,721,023 | $21,827,142 | $-8,708,614 |
| 2021 | $3,990,807 | $10,638,729 | $16,636,977 | $-6,647,922 |
| 2020 | $11,678,298 | $21,889,542 | $25,453,948 | $-10,211,244 |
| 2019 | $15,446,044 | $21,802,879 | $26,611,393 | $-6,356,835 |
| 2018 | $9,093,139 | $22,588,583 | $17,290,389 | $-13,495,444 |
Compare Gencure with other nonprofits in Texas and across the country.